Research.Patient.info
Advanced hepatocellular carcinoma (HCC) research hub
2 indexed studies · 2 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)
This study looks at whether adding an immunotherapy drug called toripalimab to a standard targeted medicine called lenvatinib helps people with advanced liver cancer live longer. Patients take daily lenvatinib capsules alongside either toripalimab or a dummy medicine (placebo) given through a drip.
Poland · Italy - recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)
This study is looking at a new combination of medicines and a treatment called TACE for people with advanced liver cancer. It aims to see if this combination can stop the cancer from growing for at least 6 months and if it's safe.
Ireland